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presence of a fibrinolytic effect of compression.7 Finally,
there are no clinical trials to support the superiority of one
product over another.8,9 Nine months before the expira-
tion of our Institutional PCD contract, investigators from
the Section of Vascular Surgery were approached by the
Materials Management and Purchasing Departments for
assistance in identifying a PCD system for use at our aca-
demic medical center. We chose to perform an effective-
ness study as opposed to a randomized clinical trial,
because this design would allow us to evaluate the perfor-
mance of PCDs as they are routinely used at this institu-
tion. Effectiveness research does not attempt to control
variables as in a randomized clinical trial but to focus on
clinical outcomes in a variety of situations.
MATERIALS AND METHODS
We selected five evaluation criteria. In order of impor-
tance, these included the rate of DVT, compliance, patient
acceptance, nursing acceptance, and finally, cost. A matrix
was developed for this comparison (Table I). Each device
was ranked on each criterion on a scale from 1 to 5 with 1
being the most desirable ranking.
A prebid conference was held for vendors interested in
bidding for the PCD contract. The following require-
ments were identified:
1. Participation in a prospective study comparing clinical
outcomes.
2. Provision of PCD pumps and sleeves for a 30-day
period for which they would be reimbursed. (If a ven-
Thromboembolism is a major source of morbidity and
death among hospitalized patients, but it can be lowered
substantially with an effective program of prophylaxis. The
efficacy of pneumatic compression devices (PCDs) has
been demonstrated in clinical studies.1-3 Several types of
devices are available, but there is insufficient evidence to
determine selection of one over another. Purchasing deci-
sions based on economic considerations, product name
recognition, and unsupported claims of superiority are
inappropriate. Selection criteria should include evidence
that is based on clinical effectiveness: how the devices per-
form in the situation where they will be used.
Marketing claims are based on the type of compres-
sion (intermittent versus sequential) and the amount of
tissue compressed (calf versus thigh), both of which affect
blood flow volume and velocity.4-6 Manufacturers cite dif-
ferences in peak systolic velocity or volume flow as the
basis for the effectiveness of the PCDs, but we are
unaware of any convincing clinical studies that link pre-
vention of DVT with these performance criteria.
Furthermore, there are conflicting data regarding the
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Purpose: The five pneumatic compression devices (PCDs) that are marketed provide mechanical protection from deep
venous thrombosis (DVT). They differ with respect to patterns of compression and the length of the sleeve. Evidence
linking differences to clinical outcomes is lacking. Our purpose was twofold: to evaluate each of the marketed PCDs
with respect to effectiveness, compliance, and patient and nursing satisfaction and to determine whether there is a clin-
ical basis for the selection of one device over another.
Methods: Each of the marketed devices was used exclusively for a 4-week period. Patients participated in an evaluation
including venous duplex ultrasound scan, DVT risk assessment, and device evaluation. Vascular laboratory records were
used to document DVT. Compliance was measured by meters installed on all pumps. A ranking matrix was stratified
by compression pattern: rapid graduated sequential compression, graduated compression, and intermittent compres-
sion, and each device was rated by patients and nurses. 
Results: The PCDs were used in 1350 cases with a DVT rate of 3.5% ranging from 2% to 9.8% depending on the method
of compression. Patients with DVT were older (58 vs 54 years), had better compliance (67% vs 50%), and had more
compression days (11 vs 7.2). When thigh-length sleeves were used, a greater proportion of DVT occurred in the prox-
imal segments (71%) as compared with the number of proximal DVT when the calf-length devices were used (52%; P
= .21). Devices W, X, and Y had comparable rates of DVT, which were lower than those for V and Z. Compression
device Y, with calf and thigh sleeves, achieved the best overall ranking largely because of high scores for patient and
nurse satisfaction. 
Conclusion: Our data appear at odds with commonly held beliefs. We were unable to show a difference in DVT inci-
dence based on the length of the device or the method of compression. Randomized studies are needed to confirm our
findings and evaluate hypotheses derived from this study. (J Vasc Surg 2001;34:459-64.)
dor did not have a full line of foot-, calf-, and thigh-
length sleeves, the products currently used at our insti-
tution were substituted, but results from these patients
would not be included.)
3. Addition of counters to the pumps for recording
actual use.
4. Provision of inservice training and support to the
nursing staff.
The bid from each manufacturer was submitted before
initiation of the study.
After approval by the Institutional Review Board, all
patients assigned PCD prophylaxis were asked to partici-
pate. Those who agreed completed a DVT risk factor assess-
ment form (Appendix A, online only), completed a device
evaluation form (Appendix B, online only), and underwent
a venous duplex ultrasound scan before discharge. The cri-
teria for a positive venous study included lack of vein com-
pressibility and visualization of thrombus. Our laboratory
protocol requires imaging both proximal and distal lower
extremity segments including the iliac veins. The scans were
obtained once PCD use dropped below 8 h/d. The diag-
nostic vascular laboratory and radiology records were
reviewed to identify positive reports of deep venous throm-
bosis (DVT) or pulmonary embolism (PE) that may have
occurred after the study screening. This review was contin-
ued for 60 days after the close of the study to identity recur-
rent events. When a patient’s stay spanned the evaluation of
two or more product lines, the initial device was used
throughout. Data regarding additional methods of throm-
boembolism prophylaxis with standard heparin, low molec-
ular weight heparin, and antiembolism stockings were
obtained from the in-patient pharmacy and merged into the
patient profile.
The counters on each pump were monitored every 1 to
2 days, and the final pump reading was obtained when the
device was returned to Central Supply. A log of device use
was maintained for each pump indicating the dates of ser-
vice and the counter readings at initiation and conclusion.
Materials Management provided a daily list of all pumps
that were in use. At the conclusion of the study, clinical
data were compared with records for PCD use maintained
by Materials Management, and inconsistencies were
resolved. One week before the end of each 30-day period,
nursing personnel completed a device evaluation form
(Appendix C, online only). The patient and nursing sur-
veys were scored on a scale of 1 through 5. The individual
responses were subtracted from the perfect response for
each question. The differences were then totaled to obtain
an evaluation score for each subject. An average score for
each device was calculated, and these scores were ranked
on a scale of 1 through 5 for inclusion in the matrix.
Patients who did not agree to the risk assessment or ultra-
sound study still had PCD pump time monitored.
This was a prospective, observational, cohort study to
determine the clinical effectiveness of currently marketed
PCDs. Purchasing and Materials Management employees
were masked to the clinical results of the study, whereas
the Vascular Surgery investigators were masked to the eco-
nomic factors. The primary objective was to identify the
device with the best score on the ranking matrix. The
analysis of the study data involved completion of the
matrix and a stepwise decision process. If one device was
clearly more effective, that device would be selected. If
not, we would look at compliance, patient satisfaction, and
nursing acceptance. Vendors whose final matrix totals
were within 3 points of each other would then be rated on
an economic basis. Secondary analyses were conducted to
establish hypotheses for future investigation.
Data were entered into an Excel spread sheet
(Microsoft, Redmond, Wash) and analyzed with SAS soft-
ware (SAS Institute, Cary, NC). Most analyses were
descriptive, in which the mean and SD for each variable
were reported. Continuous data were analyzed with analy-
sis of variance or t tests, whereas the likelihood ratio χ2 test
and the Fisher exact test were used for dichotomous data.
Because we were attempting to generate hypotheses for
future studies, a P value of .1 was used. Sensitivity analysis
with various methods for determining the incidence of
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Table I. Matrix ranking of devices*
Device DVT Compliance Patient satisfaction Nurse satisfaction Total
V 5 1 2 2 10
W 3 2 1 1 7
X 2 4† 3 3 12
Y 1 3 5 5 14
Z 4 4† 4 4 16
The lowest rank is the most favorable.
*The points 1 to 5 equal best to worst.
†Ties were given to the lowest ranking.
Table II. Devices are classified by the pattern of com-
pression and the type of sleeves
Device Compression pattern Sleeves
V Rapid gradient sequential Calf
W Intermittent compression Foot, calf, thigh
X Gradient sequential Foot, calf, thigh
Y Gradient sequential Foot, calf, thigh
Z Intermittent compression Calf
DVT was performed to determine whether it influenced the
final matrix ranking (Appendix D, online only).
We have chosen to identify each device by the mecha-
nism of action rather than by specific names of the manu-
facturers to avoid providing a commercial advantage. In
addition, we have seen the ownership of a device move
from one vendor to another and new devices using similar
mechanisms enter the market. This should facilitate gen-
eralizability of the data. Table II lists the mechanism of
action as described by the vendor and the alphabetical
identification we assigned to each.
RESULTS
The five vendors attending the prebid conference cho-
sen to participate in the study included Venodyne
(Microtek Medical, Inc, Columbus, Miss), NuTech (KCI
Company, San Antonio, Tex), Kendall (Kendall, Mansfield,
Mass), Huntleigh (Huntleigh Healthcare, Eatontown,
NJ), and Aircast (Aircast, Inc, Summit, NJ). Two of the
vendors offered only a calf-length device, so the number of
patients in groups V and Z was significantly less than that
of the three vendors with complete lines. Patient enroll-
ment took place between April and September 1999, dur-
ing which 1350 in-patients were ordered PCDs by their
attending physician and had them delivered. Consent for
full participation was obtained from 473 patients. Duplex
screening was completed for 243 patients, which identified
29 asymptomatic cases of DVT. Thirty patients from the
study population who had symptoms of DVT underwent
diagnostic scanning, which revealed an additional 19 cases
of DVT. There was no diagnosed PE among the 1350
patients. A risk assessment was completed for 473 patients.
At least two pump readings were available for 648 patients.
The remaining patients were not admitted to the hospital
after outpatient surgery or were admitted for less than 48
hours, which did not provide sufficient time to enroll them
in the study. These patients were included in our review of
the Vascular Laboratory and Radiology data for the diag-
nosis of thromboembolism.
Deep venous thrombosis. During this period 90 cases
of DVT were diagnosed among in-patients, with 48 occur-
ring in those using PCDs. There were no deaths associated
with thromboembolism in this group. Table IV lists patient
characteristics. On average, the groups differed with respect
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to the incidence of DVT, the number of days the pumps
were in use, and the percentage of female patients.
We stratified our results first by the length of the com-
pression sleeve and then by the absence or presence of
DVT. We failed to identify a difference in patient charac-
teristics associated with the sleeve length. The incidence of
DVT was 3.6% among the 853 patients with calf-length
devices and 3.4% among the 497 with thigh-length
devices. Patients with DVT tended to be older by 4 years
and were more likely to be male (54% vs 37%). They had
more days of pump use (11 vs 7 days) and better compli-
ance (16 vs 12 h/d).
The incidence of DVT ranged from 2% to 9.8%
among the devices (P = .003). When stratified by sleeve
length, the difference remained significant among the
calf-length devices (P = .001) but not among the thigh-
length sleeves (P = .19). This was probably due to a
Type II error because there were fewer thigh-length
devices used. It is possible that we have underestimated
the incidence of asymptomatic DVT because we were
unable to complete venous duplex studies for all patients
who consented. However, by including all reports of
symptomatic DVT or diagnosis of PE, we have captured
all clinically important events. It was possible to calcu-
late the DVT rate in several ways. We performed a sen-
sitivity analysis using three different methods of
calculating the incidence rates: the total number of DVT
divided by the total number of patients, the total num-
ber of DVT divided by the total number scanned, and
the total number of DVT divided by the number con-
sented. Although the rankings differed slightly, the over-
all matrix ranking was insensitive to the method of
calculation (Appendix D, online only).
We found that the use of pharmacologic prophylaxis
was consistent across the five evaluation periods, ranging
from 17% to 23% (P = .45) and should not have influenced
the outcome. Of the 275 patients who received a second
method of prophylaxis, 229 received heparin, 27 had
stockings, and 19 had both heparin and stockings.
Nineteen patients with additional prophylaxis had DVT,
all in the heparin group. The use of additional prophylaxis,
as well as the length of the PCD sleeve and the period of
use, was managed by the attending physician because we
were evaluating the devices as they were routinely used.
Table III. Percentage of proximal DVT stratification
Proximal Distal Both % Proximal
By device
V 4 6 2 50
W 5 6 3 57
X 5 3 0 63
Y 2 2 2 67
Z 4 3 1 63
By sleeve length
Knee 11 15 5 52
Thigh 9 5 3 71
The locations of the DVT are summarized in Table II.
The percentage of DVT that were proximal versus distal
ranged from 50% to 67% depending on the vendor. When
we stratified the data according to sleeve length, we found a
higher incidence of proximal DVT among those with thigh-
length (71%) versus calf-length (52%) sleeves (P = .21).
Compliance. Counters affixed to each pump were read
every 1 to 2 days and at the time of their return to central
supply. Compliance was rated as poor if the usage was less
than 8 hours per reading, fair if it was between 8 and 16
hours, and good if it was more than 16 hours. A rating scale
of 1, 1.5, or 2 was assigned to each level, respectively. The
percentage of patients falling within each group for a par-
ticular device was multiplied by the rating and summed to
determine the compliance score that ranged from 139 to
154 (P > .05). There was no association between the inci-
dence of DVT and the percentage of patients falling into
each level of compliance for either the calf- or thigh-length
devices (P = .15 and P = .58, respectively).
Patient satisfaction. A total of 391 patients com-
pleted a seven-question survey about their experience with
PCDs. The topics included comfort, mobility, sleep inter-
ference, and noise. They were to indicate whether they
would use the device again and whether they would prefer
a once-daily injection instead of using the device. There
were statistically significant differences among the devices
with respect to all the questions except willingness to use
the device again. The level of significance ranged from a 
P value of .0001 to .01. See Appendix E (online only) for
the details of the calculation. Vendor W had the highest
level of acceptance, especially with respect to comfort and
quietness; Vendor V closely followed. Patients consistently
rated Vendor Y as the least desirable.
Nursing acceptance. Nurses completed an eight-
question survey (Appendix C, online only). They
answered questions about patient complaints, ease of
application, frequency of alarms, interference with care,
patient mobilization, and willingness to use the device.
Between 81 and 133 nurses completed each survey, and
the mean satisfaction scores ranged from 5 to 19, with 5
being the most desirable. Devices W and V were the most
preferred systems. The nurses indicated a high number of
patient complaints with Device Y and problems with appli-
cation of the device and the number of alarms. The num-
ber of patient complaints and the ease of application were
the two most important factors, with P values ranging
from .0002 to .004. Interestingly, both patients and
nurses ranked the devices in the same order.
Decision process. The completed matrix was
reviewed (Table I). With respect to effectiveness, the
analysis of variance indicated significant differences among
the devices. V and Z had a higher incidence of DVT (9.8%
and 6.5%) compared with W, X, or Y (3.2%, 2.5%, and
2%). The latter were very similar. V and Z were dropped
from further consideration because of the importance we
placed on effectiveness. Device W had the best scores for
patient and nursing acceptance and the second ranking for
compliance, resulting in the best overall ranking of 7.
Device X was next at 12, whereas Device Y had a score of
14 because of poor acceptance scores. We therefore rec-
ommended device W. These data were provided to
Purchasing and Materials Management for action.
Happily, the bid submitted by Vendor W was also the low-
est, making the decision straightforward. Vendor W
offered the most desirable product at the best price.
DISCUSSION
This study includes both clinical and economic factors. It
was conducted to ensure quality patient care at an attractive
cost. The effectiveness trial methodology was adapted to
allow us to answer our research question: Which device was
the most cost-effective in this setting? The generalizability of
our results to smaller community settings is questionable. This
is a large academic medical center that attracts a patient pop-
ulation whose risk of DVT is high. We are also a high-volume
user of PCDs. Nurses have heavy patient assignments, and we
noticed early on that the compliance estimates were low, with
most of the PCDs in use less than 12 h/d. Although this was
a significant concern, we did not attempt to influence practice
during the period of the study to avoid biasing the results.
There are several limitations to this study. 
1. Patients were not randomized. Instead, each device
was used exclusively for a 30-day period. There was no
reason to believe that patient profiles or physician
practices would differ from month to month. When
we checked this assumption, we noticed that the num-
ber of days the pump was used was higher while eval-
uating devices V and Z, and we can not explain this
finding. We also noted that the percentage of female
patients was greater in these two groups. How this
might have affected the outcome is unclear.
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Table IV. Patient characteristics stratified by device type
No. of 
Device Pump (d)* Age (y) % DVT* Risk Compliance patients
V 10.6 53.6 9.8 3.9 12.9 124
W 7.2 54.2 3.2 4.2 13.6 432
X 6.6 54.8 2.5 4.1 11.1 372
Y 6.7 53.2 2.0 4.2 12.6 297
Z 8.8 55.7 6.4 3.9 10.5 125
*P < .05.
2. There was a reduction in the number of PCDs used
during this 5-month period relative to the same period
1 year earlier and a reduction in the length of stay for
postoperative patients so that fewer patients were
enrolled.
3. The number completing the survey was lower than
anticipated. It is possible that we only captured the
opinion of those who had a very positive or negative
experience, and this may have biased the results. 
4. Many patients were discharged before undergoing the
routine ultrasound venous duplex examination. This
may have biased our estimates of the incidence of
asymptomatic DVT. By following the Diagnostic
Vascular Unit records, we were able to pick up any
symptomatic DVT.
Despite the limitations, we think that this study allowed
us to identify a brand of PCDs that provides excellent value
to our patients and institution. It is effective, the patients
and nurses find it acceptable, and the cost is reasonable.
Implementing product W meant that we changed
from an intermittent sequential compression system to a
simpler intermittent device. As a quality assurance measure
we compared the incidence of DVT during a 6-month
period before the trial with the incidence during the first
6 months of use and found no difference. There were 61
DVTs among the 11,943 admissions from April to
September 1998 (0.51%) compared with 63 of 13,228
(0.47%) from April to September 2000. There were 90
diagnosed DVTs during the study period, but these
included the asymptomatic DVT found during screening
examinations.
Some of the findings from this study raise questions
about commonly held beliefs. Many physicians think that
full-length sleeves compress a greater volume of tissue and
therefore provide a higher level of protection for patients at
higher risk. Our data did not support this belief. The inci-
dence of DVT was similar (3.4% vs 3.6%) among patients of
similar age and risk of thromboembolism. It is also assumed
that compliance is associated with effectiveness, yet we
failed to find a significant association between the hours of
use and the incidence of DVT. We have previously reported
differences among the five devices with respect to peak sys-
tolic velocity, mean systolic velocity, and peak volume flow
in normal volunteers (Society of Vascular Technology,
Orlando, Fla, August 2000). When we compared these val-
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ues with the incidence of DVT from the current study, we
found that devices that achieved the greatest percent
increase in peak systolic velocity also had the highest inci-
dence of DVT. This is a clinically untested finding that
requires further investigation, but it suggests a potential risk
of increasing DVT from excessive tissue compression.4
Much is yet to be learned about the mechanisms by
which PCDs prevent thromboembolism. As devices enter
the market, the Food and Drug Administration grants
510(k) approval based on equivalence to predicate
devices. They do not require clinical studies. As a result,
there has been little effort to study the relative value of the
various compression cycles and patterns. We found the evi-
dence from this effectiveness study convincing and suffi-
cient to support the selection of an intermittent
compression device for use at our institution and our ini-
tial quality assurance procedures appear to support the
validity of the process.
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Dr Roger T. Gregory (Virginia Beach, Va). As usual Dr
Greenfield’s team from Michigan has evaluated an important area
of venous disease. Mechanical devices are much more attractive
than pharmacologic agents for DVT prophylaxis particularly in
postoperative patients. We have used these devices in Norfolk for
over 10 years and anecdotically have never seen a case of DVT
when they were used. Routine ultrasound scanning was not used
in all our patients, however. At least no clinically significant case
of DVT was encountered.
Which is the best of the multiple devices available forms the
basis for the current study. I have three questions for you:
1. Shouldn’t venous dynamics and the instance of DVT be related?
2. Why are there several areas of disagreement between your
study and previous reports on the same subject?
3. And finally a practical question: Your data suggest that
mechanical devices do not provide an additive form of protec-
tion when used with pharmacologic prophylaxis. Why not?
DISCUSSION
I enjoyed your paper and hope this is an early report with
more definitive conclusions to follow. Thank you.
Ms Mary Proctor. Thank you very much. We were interested
in looking primarily at the effectiveness of the devices but also at
understanding the underlying mechanism of action for the effec-
tiveness of the device, and so in addition to the study of hospital-
ized patients, we conducted an evaluation of performance in
normal volunteers to look at the hemodynamic effects of the
devices. This raised more problems in our minds than we had ini-
tially because the finding indicated that devices with higher peak
velocity were the devices that had a higher incidence of DVT
among patients. This appears to fly in the face of common wis-
dom, which says that if you compress at a higher rate you clear the
vein more rapidly and more effectively. We are continuing to eval-
uate this effect.
Our data differ from others in three respects. One, the num-
ber of subjects was larger. Two, it was not a randomized study.
And three, we compared all of the available devices rather than
just one device relative to another or one device relative to
another prophylactic method. 
Finally, I did not have time in the presentation, but we did
look at additional prophylaxis in these patients to make sure that
the groups were equivalent, which they were. We found a group
of patients who had the combined use of mechanical and phar-
macologic protection who still went on to develop DVT. It is
this group of patients who will be the target of our future
research.
Dr G. Patrick Clagett (Dallas, Tex). I congratulate you; these
data are sorely needed. What was the population of patients that
you studied? Were they general surgery patients, trauma patients,
and orthopedic patients? The risk of DVT and your end point
event rate are going to be much higher depending on the popu-
lation you choose. I would suggest that if you had patients, such
as stroke patients, patients on the neurosurgery service, orthope-
dic patients, where the incidence of DVT would be much higher,
you would have a higher event rate and a more robust study. That
leads to my question: What population are you going to study
next with a head-to-head comparison?
Ms Proctor. We included all patients admitted to the univer-
sity adult hospital who were assigned by their physician to have
mechanical prophylaxis, and so it included all of the groups that
you reflected: trauma, orthopedic surgery, and medical patients.
There were about 75% surgical and 25% medical patients among
those assigned to use the devices.
Dr Thomas Brothers (Mt Pleasant, SC). Certainly any time
you make the statement that there is no difference between
groups, there is the strong chance of a type II error, especially
when there is such a low event rate. I would caution you about
some of the findings, about no difference in terms of knee-high
versus thigh-high devices.
There is a large proportion of patients who are at risk for DVT,
namely, the trauma patients, especially those with orthopedic
trauma, who, because of their orthopedic injury, cannot use the
typical type of sequential pump, only use a foot pump. I wondered
if you have any plans of evaluating some of the foot pump devices.
Ms Proctor. The foot pump devices were included in this
study; however, none of the physicians ordered those devices to
be used on any patient during that 5-month period. At earlier
points in time the trauma unit had used a foot pump but has since
come to rely on the pharmacologic prophylaxis when possible.
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